S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Why Your IRA Could Crash on January 16th? (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Why CSL Ltd Stock Could Be Worth a Look
Why Your IRA Could Crash on January 16th? (Ad)
MarketBeat: Week in Review 11/28 – 12/02
Estonia to buy US rocket artillery system in $200M deal
Why Your IRA Could Crash on January 16th? (Ad)
Rail workers say deal won't resolve quality-of-life concerns
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Why Your IRA Could Crash on January 16th? (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Why CSL Ltd Stock Could Be Worth a Look
Why Your IRA Could Crash on January 16th? (Ad)
MarketBeat: Week in Review 11/28 – 12/02
Estonia to buy US rocket artillery system in $200M deal
Why Your IRA Could Crash on January 16th? (Ad)
Rail workers say deal won't resolve quality-of-life concerns
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Why Your IRA Could Crash on January 16th? (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Why CSL Ltd Stock Could Be Worth a Look
Why Your IRA Could Crash on January 16th? (Ad)
MarketBeat: Week in Review 11/28 – 12/02
Estonia to buy US rocket artillery system in $200M deal
Why Your IRA Could Crash on January 16th? (Ad)
Rail workers say deal won't resolve quality-of-life concerns
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Why Your IRA Could Crash on January 16th? (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Why CSL Ltd Stock Could Be Worth a Look
Why Your IRA Could Crash on January 16th? (Ad)
MarketBeat: Week in Review 11/28 – 12/02
Estonia to buy US rocket artillery system in $200M deal
Why Your IRA Could Crash on January 16th? (Ad)
Rail workers say deal won't resolve quality-of-life concerns
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs

Revance Therapeutics - RVNC Stock Forecast, Price & News

$22.15
+0.39 (+1.79%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$21.23
$22.35
50-Day Range
$20.30
$30.66
52-Week Range
$11.27
$30.95
Volume
724,526 shs
Average Volume
1.24 million shs
Market Capitalization
$1.82 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.90

Revance Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
71.1% Upside
$37.90 Price Target
Short Interest
Bearish
12.45% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$297,770 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.38) to ($3.32) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.52 out of 5 stars

Medical Sector

145th out of 1,034 stocks

Pharmaceutical Preparations Industry

53rd out of 502 stocks

RVNC stock logo

About Revance Therapeutics (NASDAQ:RVNC) Stock

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Receive RVNC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RVNC Stock News Headlines

Nanostics Announces New Member of Board of Directors
Next-Generation Fighter Jets?!? (Must See)
The U.S. Department of Defense is using one shocking company to develop breakthrough tech...And at less than $2... this could be the last bargain on the market. Get the Details Here (Act Fast... a Key Announcement in December Could Send It Rocketing) pixel
What 8 Analyst Ratings Have To Say About Revance Therapeutics
Next-Generation Fighter Jets?!? (Must See)
The U.S. Department of Defense is using one shocking company to develop breakthrough tech...And at less than $2... this could be the last bargain on the market. Get the Details Here (Act Fast... a Key Announcement in December Could Send It Rocketing) pixel
Revance Therapeutics's Earnings: A Preview
Revance Bets on a Better Botox
What 7 Analyst Ratings Have To Say About Revance Therapeutics
See More Headlines
Receive RVNC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RVNC Company Calendar

Last Earnings
11/09/2021
Today
12/03/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/27/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RVNC
Employees
495
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$37.90
High Stock Price Forecast
$65.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+71.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$-281,310,000.00
Net Margins
-251.92%
Pretax Margin
-251.27%

Debt

Sales & Book Value

Annual Sales
$77.80 million
Book Value
$1.77 per share

Miscellaneous

Free Float
78,078,000
Market Cap
$1.82 billion
Optionable
Optionable
Beta
0.52

Key Executives

  • Mr. Mark J. FoleyMr. Mark J. Foley (Age 57)
    CEO & Director
    Comp: $1.4M
  • Mr. Dustin S. Sjuts (Age 43)
    Pres
    Comp: $829.22k
  • Mr. Tobin C. SchilkeMr. Tobin C. Schilke (Age 47)
    CFO & Principal Accounting Officer
    Comp: $633.61k
  • Mr. Aubrey RankinMr. Aubrey Rankin (Age 46)
    Consultant
    Comp: $881.24k
  • Jessica Serra
    Head of Investor Relations & ESG
  • Mr. Dwight MoxieMr. Dwight Moxie (Age 45)
    Sr. VP, Gen. Counsel & Corp. Sec.
  • Ms. Jeanie D. Herbert
    Sr. Director of Investor Relations & Corp. Communications
  • Ms. Taryn Conway
    VP of Marketing
  • Mr. Justin Ford
    Sr. VP of HR & Head of People
  • Ms. Azita Nejad
    Sr. VP of Technical Operations













RVNC Stock - Frequently Asked Questions

Should I buy or sell Revance Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RVNC shares.
View RVNC analyst ratings
or view top-rated stocks.

What is Revance Therapeutics' stock price forecast for 2023?

7 equities research analysts have issued 12 month price objectives for Revance Therapeutics' shares. Their RVNC share price forecasts range from $24.00 to $65.00. On average, they predict the company's stock price to reach $37.90 in the next year. This suggests a possible upside of 71.1% from the stock's current price.
View analysts price targets for RVNC
or view top-rated stocks among Wall Street analysts.

How have RVNC shares performed in 2022?

Revance Therapeutics' stock was trading at $16.32 on January 1st, 2022. Since then, RVNC stock has increased by 35.7% and is now trading at $22.15.
View the best growth stocks for 2022 here
.

When is Revance Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our RVNC earnings forecast
.

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics, Inc. (NASDAQ:RVNC) released its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported ($1.10) earnings per share for the quarter, beating the consensus estimate of ($1.15) by $0.05. The biopharmaceutical company had revenue of $19.75 million for the quarter, compared to the consensus estimate of $20.03 million. Revance Therapeutics had a negative net margin of 251.92% and a negative trailing twelve-month return on equity of 461.54%. During the same quarter last year, the business posted ($1.34) EPS.

What is Mark Foley's approval rating as Revance Therapeutics' CEO?

7 employees have rated Revance Therapeutics Chief Executive Officer Mark Foley on Glassdoor.com. Mark Foley has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Revance Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Myovant Sciences (MYOV), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Sangamo Therapeutics (SGMO).

What is Revance Therapeutics' stock symbol?

Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."

Who are Revance Therapeutics' major shareholders?

Revance Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.24%), State Street Corp (1.96%), Two Sigma Investments LP (1.36%), Jennison Associates LLC (1.47%), Jacobs Levy Equity Management Inc. (1.12%) and Rice Hall James & Associates LLC (1.23%). Insiders that own company stock include Angus C Russell, Aubrey Rankin, Dwight Moxie and Mark J Foley.
View institutional ownership trends
.

How do I buy shares of Revance Therapeutics?

Shares of RVNC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Revance Therapeutics' stock price today?

One share of RVNC stock can currently be purchased for approximately $22.15.

How much money does Revance Therapeutics make?

Revance Therapeutics (NASDAQ:RVNC) has a market capitalization of $1.82 billion and generates $77.80 million in revenue each year. The biopharmaceutical company earns $-281,310,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis.

How many employees does Revance Therapeutics have?

The company employs 495 workers across the globe.

How can I contact Revance Therapeutics?

Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The official website for the company is www.revance.com. The biopharmaceutical company can be reached via phone at (615) 724-7755, via email at jherbert@revance.com, or via fax at 510-742-3401.

This page (NASDAQ:RVNC) was last updated on 12/3/2022 by MarketBeat.com Staff